Posted by Michael Wonder on 10 Jul 2022
Prices and clinical benefit of national price negotiated anti-cancer medicines in China
8 July 2022 - High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems.
Since 2017, China has implemented national price negotiations for medicines, relying on evidence from health technology assessments.
We aim to assess the relation between negotiated price and value of anticancer medicines listed in China’s National Reimbursement Drug List.
